RxDoctor Payments Data

Earl Wilson, MD

Neurology · Bristol, TNNPI 1568455244

Payments from drug & device makers

$16,601in general payments, 2019–2025

Across 860 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Novartis$915
  • Lilly USA, LLC$809
  • Neurelis, Inc.$665
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$16,45799%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.74$2,039
AbbVie(2 entities)136$1,766
AstraZeneca(2 entities)54$1,221
Novartis49$915
Lilly USA, LLC45$809
Neurelis, Inc.21$665
MDD US Operations, LLC34$641
Biogen36$635
Lundbeck LLC28$533
Teva Pharmaceuticals USA, Inc.28$490
Genentech USA, Inc.21$412
Acadia Pharmaceuticals Inc26$388
Eisai Inc.19$376
TG Therapeutics, Inc.10$357
Bristol Myers Squibb18$345
Amgen(2 entities)14$301
Sunovion Pharmaceuticals Inc.20$300
Kyowa Kirin, Inc.14$296
Pfizer15$257
Argenx US, Inc.13$249
Neurocrine Biosciences, Inc.14$240
Biohaven Pharmaceuticals, Inc.13$227
SK Life Science, Inc.8$218
Sanofi9$201
Biohaven Pharmaceutical Holding Company Ltd.11$194
Upsher-smith Laboratories LLC11$177
Supernus Pharmaceuticals, Inc.8$176
Amneal Pharmaceuticals LLC7$132
Avanir Pharmaceuticals, Inc.8$127
Greenwich Biosciences, Inc.4$126
Jazz Pharmaceuticals Inc.5$122
Merz Pharmaceuticals, LLC5$116
Corium, LLC5$101
Impel Pharmaceuticals Inc.4$99
Mallinckrodt Hospital Products Inc.5$99
E.r. Squibb & Sons, L.L.C.6$89
Johnson & Johnson5$88
CSL Behring4$87
Otsuka America Pharmaceutical, Inc.4$80
Catalyst Pharmaceuticals, Inc.3$78
Sumitomo Pharma America, Inc.5$75
EMD Serono, Inc.4$64
Mallinckrodt Enterprises LLC3$54
Takeda Pharmaceuticals U.S.A., Inc.4$51
Ipsen Biopharmaceuticals, Inc2$47
Adamas Pharmaceuticals, Inc.2$44
GE HealthCare1$43
Harmony Biosciences LLC2$42
Avion Pharmaceuticals2$42
Assertio Therapeutics, Inc.3$41
Vanda Pharmaceuticals Inc.2$40
Merz North America, Inc.2$35
Aprecia Pharmaceuticals, LLC2$32
Averitas Pharma Inc.1$29
Arbor Pharmaceuticals, Inc.2$28
Aucta Pharmaceuticals, Inc.1$21
Banner Life Sciences, LLC1$20
Livanova USA, Inc.1$20
Grifols USA, LLC1$20
Immedica Pharma US, Inc.1$20

How this compares

$16,601 in reported general payments places this provider in the 65th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$52,899
Medicare patients
278
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate33$175,028
BotoxOnabotulinumtoxina42$64,111
Nurtec OdtRimegepant Sulfate33$36,250
UbrelvyUbrogepant28$32,062
Emgality PenGalcanezumab-Gnlm31$29,368
Aimovig AutoinjectorErenumab-Aooe28$21,235
BriviactBrivaracetam15$20,309
RexultiBrexpiprazole11$18,772
Glatiramer Acetate13$18,002
Lacosamide86$11,468
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone15$7,115
TrintellixVortioxetine Hydrobromide12$5,197
TegretolCarbamazepine13$4,368
Levetiracetam100$2,892
Carbamazepine ErCarbamazepine14$2,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$388$175,02833 claims
AbbVieBotox, Ubrelvy$1,766$96,17270 claims
PfizerNurtec Odt$257$36,25033 claims
UCB, Inc.Briviact$2,039$20,30915 claims
Otsuka America Pharmaceutical, Inc.Rexulti$80$18,77211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$51$5,19712 claims
Upsher-smith Laboratories LLCTopiramate$177$54058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 361 neurology providers in Tennessee.

Other neurology in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →